Thursday, August 21, 2014
   
Text Size

Site Search powered by Ajax

image image image image
Seeking a Cure for HPV With DNA-targeted therapeutics. HPV may be best known for its role as the cause of cervical cancer – the second leading cause of cancer deaths among women worldwide. But it also causes genital and other warts. Current treatments are primitive and ineffective. The scientists at NanoVir are developing treatments for HPV using DNA-Targeted therapies. Learn more about the science behind our research.
Lead By Extensive Pharmaceutical & University Research Credentials NanoVir was founded in 2003 by Drs. Chris Fisher and James Bashkin, both of whom bring extensive pharmaceutical and university research credentials to the company. Their HPV research has been consistently recognized by the scientific community through invited presentations and funding.

   
Research Recognized by the Scientific Funding Community NanoVir's promising research into DNA-targeted treatments for HPV has been consistently recognized by the scientific funding community. ( To see issued  patents, click here.) 2008 -2010 Phase 2 STTR Grant - $3,000,000. This grant will enable development of broad spectrum anti HPV compounds RO1 Grant - $1,830,000. This grant allows basic studies of antiviral mechanisms of actions
 
State-of-theArt Facilities & Resources The biological laboratory of NanoVir is located at the Southwest Michigan Innovation Center in Kalamazoo, Michigan,  a  58,000 square foot multi-tenant facility.  NanoVir occupies 1200 square feet of laboratory space with state-of-the art equipment, biological safety level 2 containment, and additional shared equipment available.